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Colorectal cancer (CRC) is presently one of the most common causes of cancer-related death in our setting and aﬀects a
great number of people each year. Screening strategies are commonly used but they do not seem enough to avoid CRC
development or prevent completely its mortality. Because of this fact other prevention strategies have gained interest in recent
years. Chemoprevention seems to be an attractive option in this setting and several drugs have been studied in this ﬁeld. This
review is focused on salicylates, nonsteroidal anti-inﬂammatory drugs (NSAIDs) and cycloxygenase-2 inhibitors (COXIBs), whose
mechanism of action could be directly related to colon cancer chemoprevention.
1.Background
Colorectal cancer (CRC) is the second leading cause of death
intheU.S.andaﬀectsapproximatelyonemillionpeopleeach
year, with a 5-year survival rate of 62% [1]. Approximately
20% of the cases of CRC have familial aggregation with more
than two ﬁrst-degree family members aﬀected, whereas 5–
10% occur in the context of a hereditary syndrome [2].
The development of colorectal cancer is a complex
process involving multiple molecular pathways, since the
formation of adenomas to the development of carcinoma
in the digestive tract (the so-called “adenoma-carcinoma
sequence”), in a process that can last several decades [3].
Thus adenomas are considered a surrogate variable for the
development of CRC in clinical trials.
Althoughscreeningstrategies(bloodinstool,endoscopic
and CT-colonoscopy) have supposed a great advance in the
early detection of these tumours, they are associated with
inconveniences such as their cost and associated morbidity.
Moreover screening does not necessarily prevent the devel-
opment of cancer or prevent mortality. Therefore, interest in
primary prevention research has increased in recent years.
In this regard, multiple attempts to modify lifestyle and
dietary factors to try to reduce the incidence of cancer
have been promoted. However, some studies, many of them
observational or case-control, have yielded conﬂicting data
[3]. Consequently, in the past 20 years, chemoprevention
studies have grown in importance.
Cancerchemopreventionisdeﬁnedastheuseofchemical
agents in healthy individuals to block, reverse, or delay
the development of invasive cancer. Although several drugs
have been studied, this review focuses on salicylates and
nonsteroidal anti-inﬂammatory drugs (NSAIDs), as they
constitute a group of agents whose mechanism of action
could be directly related to colon cancer chemoprevention.
Both treatment groups are inhibitors of the cyclooxygenase
(COX) enzyme responsible for the transformation of arachi-
donic acid to prostaglandins, which are involved in cell
proliferation and apoptosis [4].
In humans, three isoforms of the COX enzyme exist.
COX1 is expressed constitutively in all tissues and is involved
in maintaining the integrity of the gastric mucosa and
platelet aggregation, among other functions. The function
of COX3 remains to be determined, whereas the expression
of COX2 is inducible in both inﬂammatory processes
and tumorigenesis. Thus, COX2 is overexpressed in colon
tumours and adenomas, with expression not observed in
normal gastrointestinal mucosa. The mechanism of action
of salicylates and NSAIDs as chemopreventive agents are
not fully understood; however it is postulated that they2 The Scientiﬁc World Journal
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Figure 1: Scheme of COX-dependent and-independent mecha-
nisms related with NSAID and ASA.
act in both COX-dependent and -independent mechanisms
(Figure 1). In COX-dependent mechanisms, COX inhibition
produces a decrease in the levels of prostaglandins and their
derivatives (prostacyclins and thromboxane), producing a
decrease in the processes involved in cell proliferation. Con-
versely, COX-dependent mechanisms also lead to an increase
in the level of arachidonic acid, which promotes apoptosis.
Furthermore, experimental studies have shown that NSAIDs
induce apoptosis in tissues that do not express the COX
enzyme. These COX-independent mechanisms are still being
studied and may involve diﬀerent pathways like NFκB, the
peroxisome-γ proliferator-activated receptor (PPAR) and its
ligands and could also interfere with angiogenesis [4, 5].
This review will address the scientiﬁc evidence in ran-
domised clinical trials for these agents in both sporadic and
hereditary CRC chemoprevention ﬁelds.
2. Sporadic Colorectal Cancer
Sporadic CRC represents 75% of the total CRC cases and is
the third most common cancer in the world and the second
leading cause of cancer death [6]. Adenoma is the precursor
lesion to CRC in a sequence that may last 10–15 years.
2.1. Aspirin (ASA). The role of ASA in chemoprevention
was ﬁrst provided by Kune et al. in a case-control study in
1988, where an odds ratio (OR) of 0.53 for CRC incidence
was observed for chronic users of aspirin compared with
nonusers [7]. Since the publication of this report, other
epidemiological observational studies have shown similar
results regarding the incidence of CRC and the development
of adenomas.
In response to these studies, randomised trials were
designed to evaluate the role of aspirin in preventing cancer.
Two of the studies determined the incidence of CRC in
large healthy populations and were unable to demonstrate a
chemopreventive eﬀect for ASA. The ﬁrst was the Physicians’
Health Study (PHS), a blind, randomised study designed
to test the eﬀect of low doses of aspirin on the incidence
of cardiovascular events and CRC [8]. In 1993, Gann et al.
publishedtheresultsofCRCincidenceafter5yearsoffollow-
up [9]. In this study, 22071 healthy men were randomised
to receive either placebo or 325mg of aspirin every other
day. The primary endpoints of incidence of invasive CRC
(RR 1.15, 95% CI 0.80–1.65) and the incidence of adenomas
(RR 0.85, 95% CI 0.68–1.10) were both negative. In 1998,
St¨ urmer et al. published an update of these data over a 12-
yearperiod, demonstrating alackofeﬀectwithanRRo f1.03
(95% CI 0.83–1.28) for CRC incidence [10].
The second study, by Cook et al. was published in 2005
[11]. In this study, 39876 healthy women were randomised
to receive placebo or 100mg aspirin every other day. The
endpoints of the study were to establish (1) the incidence
of invasive cancer in any location and (2) the incidence of
breast cancer, CRC, and lung cancer. The study was unable
to demonstrate an eﬀect, with an RR of 1.01 for any cancer
and an RR of 0.97 (95% CI 0.77–1.24, P = 0.08) for CRC
incidence.
In 2003, under the assumption that the dose used in
these two studies was not optimal to test the power of
ASA in chemoprevention, three studies were simultane-
ously published from selected populations (with the use of
colonoscopy at baseline and follow-up). The main objective
was to correlate the eﬀect of diﬀerent doses of ASA with
the incidence of adenomas. The ﬁrst study by Baron et al.
explored the eﬀects of two doses of aspirin (81mg or 325mg
twice daily) versus placebo in 1121 patients with a recent
history of adenomas [12]. The study was positive for the
primary endpoint (detection of one or more adenomas at
ﬁrst colonoscopy) at the 81mg dose (38% versus 47% in
the placebo arm, P = 0.04). Moreover, the RR for the
incidence of adenomas was 0.81 (95% CI 0.69–0.96) with
a 40% reduced risk for advanced lesions at the 81mg dose.
There was no statiscally signiﬁcant diﬀerence in the risk of
death or risk of bleeding compared with placebo.
In the second study, APPAC study, 272 patients with a
personal history of colorectal adenomas were randomised to
receive 160mg or 300mg of lysine acetylsalicylate or placebo
for 4 years [13]. The study was not designed to study the
diﬀerences between the two doses of salicylates and was
negative at one year of follow-up with an RR of 0.73 (95%
CI 0.52–1.04, P = 0.08) for the incidence of adenomas.
The third study, by Sandler et al., was published in
2003. In this trial, 635 patients received placebo or 325mg
ASA daily. It was closed prematurely after the ﬁrst interim
analysis, as the main objective was achieved. The incidence
of 1 or more adenomas was 17 versus 27% (P = 0.004)
with an RR of 0.65 [14]. No signiﬁcant diﬀerences in the size
of polyps or incidence of advanced adenomas (larger than
1cm or the presence of villous component) were found. The
population in this study included patients with a personal
history of CRC (Dukes A, B and C), a high-risk population
that may partially explain these results (Table 1).
Subsequently, a meta-analysis of four studies (the three
published in 2003 with an additional one published in 2008
[15] and positive for ASA) was published in 2009 [16]. InThe Scientiﬁc World Journal 3
Table 1: Results of colorectal cancer and adenoma incidence in aspirin trials.
Study Year Cohort N◦ cases Intervention End Point RR
PHS (Gann) 1993 Healthy 22071 325mg every other day versus placebo CCR incidence 1.15
0.80–1.65
PHS (St¨ urmer) 1998 Healthy 22071 325mg every other day versus placebo CCR incidence 1.03
0.83–1.28
Cook et al. 2004 Healthy 39876 100mg every other day CCR incidence 0.97
0.77–1.24
Baron et al. 2003 Prior adenoma 1121 81mg versus 325mg daily versus placebo Adenomas incidence 0.81∗
0.69–0.96
Sandler et al. 2003 Prior CCR 635 325mg daily versus placebo Adenomas incidence 0.65
0.46–0.91
APPAC 2003 Prior adenoma 272 160mg versus 325mg versus placebo∗∗ Adenomas incidence 0.73
0.52–1.04
∗Positive for 81 mg arm. ∗∗Negative for both arms.
this study, with a population of 2698 and a median follow-
up of 33 months, the RR for the incidence of adenomas
was 0.83 (95% CI 0.72–0.96), and the incidence of advanced
lesions was 0.72 (95% CI from 0.57 to 0.90). The number
of CRCs diagnosed was low, with no statistically signiﬁcant
diﬀerence compared with the placebo arm. Although the
comparisonbetweenthelowdose(450patients)andthehigh
dose (1228 patients) of aspirin appeared to show a greater
eﬀect for the lower doses, these data should be interpreted
with caution due to the small number of trials included in
the meta-analysis. Serious side eﬀects were infrequent, and
no diﬀerence in terms of gastrointestinal toxicity was noted.
However,12individualssuﬀeredfromastroke,allintheASA
group (P = 0.02).
The heterogeneity in terms of selection criteria, study
population as well as dose and duration of treatment in
the previous studies made it diﬃcult to draw conclusions
on the clinical use of ASA. The U.S. Preventive Services
Task Force (USPSTF) conducted a meta-analysis, published
in 2007, that included randomised trials, case-control, and
cohort studies [17]. This meta-analysis established an RR
for adenoma incidence of 0.82 (95% CI 0.7–0.95) and
a decrease in CRC incidence of 22% (for the cohort
studies). Mortality data were limited and inconsistent; thus,
conclusions were not made. In terms of toxicity, the use of
aspirin was associated with an increased risk in the incidence
ofgastrointestinalbleedingwithanRR1.5–3,whichwasdose
dependent (higher for higher doses). In the analysis of the
data, the beneﬁt of aspirin was greater with higher doses
compared with those used for cardiovascular prevention.
Furthermore, the beneﬁt was higher for the high-risk CRC
population (family history) and for prolonged treatment.
Subsequent to this meta-analysis, few additional studies
have been published. Only two studies by by Flossman [18]
and Rothwell [19] provide data on prolonged treatment.
Both studies, with 20-year follow-up in a population cohort
from cardiovascular prevention studies (healthy population
with no history of previous adenomas), studied CRC
incidence as the primary endpoint. With 7588 and 14033
patients enrolled, respectively, and with diﬀerent doses of
aspirin (30mg–1200mg) for a median of 5-6 years, both
studiesdemonstrateabeneﬁtinCRCincidencewithasimilar
HR (0.74 and 0.76, resp.). When the analysis was separated
by intervals of 10 years, the beneﬁt of ASA occurred mainly
in the second decade. The study by Rothwell et al. also
demonstrated a reduction in CRC mortality with an HR
of 0.65 (0.48 to 0.88, P = 0.005). However, none of the
initial studies were designed to study CCR incidence, as they
were cardiovascular preventive studies conducted prior to
the colonoscopy screening era. Thus, these data should be
interpreted with caution.
Basedonthedatapublishedtodate,wecanconcludethat
aspirin is eﬀective in reducing adenomas and CRC incidence
(modestly) and that its beneﬁt is higher in high-risk
populations, with an acceptable safety proﬁle excluding risk
populations for bleeding. It remains to be determined what
the optimal dose and duration of treatment are and whether
this strategy is associated with a reduction in CRC mortality
with an acceptable toxicity proﬁle for healthy individuals.
2.2. Cyclooxygenase-2 Inhibitors (COXIBs). The selective in-
hibition of the COX2 isoform by COXIBs makes these drugs
attractive for preventive studies to minimise side eﬀects,
such as the gastrointestinal toxicity observed with COX1
inhibition.
After data from approximately 40 observational studies
demonstrated the utility of COXIBs as chemopreventive
agents in patients with familial adenomatous polyposis [3],
three randomised trials with similar designs (APPROVe,
APC, and PreSAP) were launched between 1999 and 2000.
Withaﬁve-yearfollow-up,thesestudiesexaminedtheroleof
diﬀerent COXIBs for three years in individuals with a recent
history of adenomas. The main objective for all three studies
was incidence of adenomas, with the secondary objectives of
incidenceofadvancedadenomas(whichincludedcarcinoma
in situ and invasive carcinoma) and the number and size of
polyps. The three studies, despite being positive for its main
objective, were closed early in 2004 after a safety analysis
demonstratedanincreaseincardiovasculareventsinsomeof
them, leading to a withdrawal of rofecoxib from the market.
The APPROVe study, which randomised 2587 patients to
receive placebo or 25mg of rofecoxib daily, showed an RR4 The Scientiﬁc World Journal
Table 2: Results in adenoma incidence in COXIB trials.
Study Year Cohort N◦ cases Intervention End point RR
APPROVe 2006 Prior adenoma 2587 25mg rofecoxib versus placebo Adenoma incidence 0.76
0.69–0.83
APC 2006 Prior adenoma 2035 200mg bid versus 400mg bid versus placebo∗ Adenoma incidence 0.67
0.55
PreSAP 2006 Prior adenoma 1561 400mg once versus placebo Adenoma incidence 0.64
0.56–0.75
∗Positive for both arms.
of 0.76 (95% CI 0.69–0.83) for its main objective [20]. The
safety analysis of this study initiated the safety analysis of the
others, after presenting an RR for cardiovascular events of
1.92 (1.19–3.11). In parallel, the APC trial comparing two
doses of celecoxib (200mg versus 400mg twice daily) versus
placebo showed a reduction for adenoma incidence for the
two doses studied (RR 0.67 for 200mg dose and 0.55 for
4 0 0m gd o s e )a sw e l la sar e d u c t i o nf o ra d v a n c e da d e n o m a
incidence (RR 0.43 and RR 0.34, resp.) [21]. However, a
signiﬁcant increase in the incidence of cardiovascular events
was again reported, with an RR of 2.6 and 3.4 for the low
and high dose of celecoxib, respectively. After 5 years of
follow-up, an update of the data was published in 2009. In it,
the chemopreventive eﬀect on adenoma incidence remained
with celecoxib use, with an RR of 0.71 for the low dose and
0.62 for the high dose. However, the cardiovascular risk also
remained, with an RR of 1.6 (1–2.5) for the 200mg dose
and 1.9 (1.2–3.1) for the 400mg dose [22]. The last study,
PreSAP trial, ran parallel to the APC [23]. It randomised 2:1
to receive 400mg single dose of celecoxib (933 patients) or
placebo (628 patients). The RR for the primary endpoint
was 0.64, and 0.49 for advanced adenoma incidence; both
are signiﬁcant. This study was also closed in 2004, although
the data did not demonstrate an increase in cardiovascular
events with an RR of 1.30 (0.65–2.62). Thirty-ﬁve patients
died due to cardiovascular events or had an episode of
heart failure, acute myocardial infarction, or stroke (23
in the experimental group (2.5%) and 12 in the placebo
group (1.9%)). A single explanation responsible for the
diﬀerences between the two trials of celecoxib in the rate of
cardiovascular events does not exist, although the diﬀerence
in dosage and method of administration may explain the
diﬀerences.
The complete analysis of the cardiotoxicity and cardio-
vascular event incidence of these trials has been published in
several articles (Table 2)[ 24, 25].
With all these data, in 2007, the USPSTF published a
new meta-analysis of the use of NSAIDs and COXIBs in the
chemoprevention ﬁeld and developed its recommendations
based on the analysis of the data published in randomised
trials, cohorts, and case-control studies [26]. The meta-
analysis conﬁrmed the eﬀectiveness of COXIBs in adenoma
prevention (RR 0.72, CI 0.68–0.77) and advanced lesion
incidence; however, the cardiovascular risk associated with
their use prevented the recommendation of their use as
chemopreventives except for special groups at high risk
of CRC. There are no studies published regarding CRC
incidence and mortality with these drugs.
Although there is a lack of comparative studies between
ASA,NSAIDs,andCOXIBs,COXIBsappeartohaveagreater
eﬀectaschemopreventiveagentsinCRC.However,themajor
side eﬀects of COXIBs, mainly cardiovascular, limit their use
in healthy individuals.
2.3. Non Steroidal Anti-Inﬂammatory Drugs (NSAIDs). The
datasupportingtheuseofotherNSAIDsaschemopreventive
agents in CRC come from observational, cohort, and case-
control studies. The previously discussed Rostom’s meta-
analysis described a reduction in CRC incidence of 30–40%
and a reduction in adenoma incidence of approximately 45–
35% with these drugs [26]. However, they maintain the gas-
trointestinal toxicity of aspirin, with an ulcer complication
rate of 1.5% per year. Other meta-analyses have suggested
that a cardiovascular toxicity proﬁle comparable to that of
COXIBs is present with NSAID use, especially in relation
to dose and duration of treatment [27]. Therefore, the
use of NSAIDs as chemopreventive agents currently is not
recommended due to the potential toxic side eﬀects.
The combination of diﬀerent chemopreventive agents is
an attractive strategy that would increase the eﬀectiveness
of these agents while minimising their side eﬀects. In
2008, a study combining the use of sulindac (NSAID) and
diﬂuoromethylornithine (an inhibitor of polyamides synthe-
sis) was published. The study yielded positive results in a
population with a recent history of adenomas [28]. An RR of
0.30 (95% CI 0.18–0.49) was obtained for its main objective
(adenomaincidence)whilea92%reductionriskinadvanced
lesions with no signiﬁcant diﬀerences in side eﬀects was
also observed. However, an analysis of cardiovascular safety
was published a year later, and an increase in cardiovascular
events was observed in subjects with cardiovascular risk
factors (7 patients in the experimental arm versus 1 patient
intheplaceboarm)[29];thus,thisstrategy,whilepromising,




FAP is an autosomal dominant inherited disease caused by
mutations in the APC gene on chromosome 5 [30]. It is
the most common polyposis syndrome, with a prevalence
of 1/10.000, which accounts for approximately 0.5–1% of
the total CRC cases. It is characterised by the presence, at
an early age, of multiple adenomatous polyps in the colonThe Scientiﬁc World Journal 5
and rectum (hundreds or thousands), with a cumulative
risk of CRC development of nearly 100% in the fourth to
ﬁfth decade of life, if not detected and treated early [31].
Prophylactic surgery (pancolectomy with ileal reservoir) is
the main strategy for the surveillance and treatment of these
patients; however, it does not completely eliminate the risk
of developing CRC and does not eliminate the need for
an exhaustive follow-up. In addition, there is an associated
morbidity with the surgery, and the young age at which the
surgeryisusuallyperformedhasimplications onthephysical
and psychological development of these patients. Therefore,
interest has developed regarding chemoprophylaxis that
could delay the time of surgery.
In this syndrome, it is diﬃcult to conduct large studies
with a large number of patients; thus, scientiﬁc evidence is
often based on observational and small phase II/III trials.
Currently, the drugs with the most evidence as chemopre-
ventive agents in FAP patients are sulindac (NSAIDs) and
COXIBs.
3.1. Sulindac. In the 1980s, the ﬁrst case reports demon-
strating nearly complete regression of adenomatous polyps
in families with FAP treated with sulindac were published
[32, 33]. Based on these reports, the ﬁrst randomised trial
of sulindac versus placebo was published in 1991 [34].
In the trial, 20 patients, all with prophylactic surgery and
persistence of the rectum, were randomised to receive either
sulindac 300mg daily (10 patients) or placebo (10 patients)
for two months. A reduction in rectal polyp incidence
(P<0.01) was observed, with complete regression in 6
patients of the experimental arm. The following studies
were conducted on populations without prior prophylactic
surgery. Two studies conducted by the same research group,
Giardiello et al., were published in 1993 and 2002 [35, 36].
With determination of the number of polyps as the main
objective, the two studies showed diﬀerent results. In the ﬁrst
report,22patients(18ofthemwithoutprophylacticsurgery)
were randomised to receive either 150mg of sulindac twice
daily or placebo for 9 months. Although there were no
signiﬁcant diﬀerences in the demographic characteristics of
the two arms, the placebo group had a greater number
of polyps at baseline (53 versus 28). After 9 months of
treatment, there was a reduction in the number (44%, P =
0.014) and size of polyps (35%, P<0.001). These eﬀects
could be observed after three months of treatment with a
maximum aﬀect after six months but was not maintained
after completion of treatment. The rate of side eﬀects was
similar in both arms. The second study, published by the
same group in 2002, was negative. Forty-one patients with
PAF, but without phenotypic expression, were randomised
to receive 75mg or 150mg of sulindac twice daily (according
to body weight) or placebo for 48 months. In addition,
rectal biopsies were performed to determine the level of
prostaglandins. No signiﬁcant diﬀerences in the number or
size of polyps between the two arms were observed, although
a signiﬁcant decrease in prostaglandin levels was reached
in the group treated with sulindac. The treatment was well
tolerated, with no signiﬁcant diﬀerences in side eﬀects.
Data from additional cohort studies and small, ran-
domised trials have reproduced similar results [37]. While
treatment with sulindac appears to induce regression in the
number and size of polyps, the eﬀect appears to be restricted
to the duration of treatment. There are insuﬃcient data
available regarding the use of sulindac or other NSAIDs
for chemoprevention in the long term, and there are
no data on CRC incidence and mortality; thus, general
recommendations cannot be made for using sulindac in
patients with FAP at this time.
3.2. COXIBs. After the data of animal models showing the
role of COXIBs in chemoprevention [37], Steinbach et al.
published a phase III trial testing a COXIB, celecoxib, as a
chemoprophylactic agent in patients with FAP [38]. Seventy-
seven patients, without surgery and with polyps at the
baseline colonoscopy, were randomised 2:2:1 to receive
either 100mg or 400mg of celecoxib twice daily or placebo
for six months. In the demographic characteristics, patients
in the 800mg arm were signiﬁcantly younger (33.1 years
versus 38.6 years, 39.9 years in the placebo arm, P = 0.04).
The study was positive for the 800mg dose with a 28%
reduction in the number of polyps (P = 0.003) and a 30.7%
r e d u c t i o ni np o l y pb u r d e n( P = 0.001). In global terms,
treatment was well tolerated, with diarrhoea and abdominal
pain as the most frequent side eﬀects, without signiﬁcant
diﬀerences with the placebo arm. These results led to the
approval of celecoxib by the FDA as a chemopreventive agent
in families with FAP.
After the Steinbach study, additional COXIBs were
studied. In 2003, two studies testing 25mg of rofecoxib were
published by both Higuchi et al. [39] and Hallak et al. [40].
Although these studies were small, with 21 and 8 patients
enrolled in each, respectively, both included patients who
had undergone colectomy (Higuchi, n = 13; Hallak, n = 5).
Both studies conﬁrmed the ﬁndings of Steinbach, with a
signiﬁcant reduction in the number and size of the polyps.
The treatment was well tolerated, and the most common
side eﬀects were diarrhoea and abdominal pain with no
signiﬁcant diﬀerences. Interestingly, the Hallak study was
the ﬁrst trial with treatment beyond one year (median 16
months)showingmaintenanceofthechemopreventiveeﬀect
with an acceptable clinical tolerance. However, rofecoxib was
withdrawn from the market in 2004 after cardiovascular
toxicitywasreportedinotherstudiesofchemoprevention(as
described previously in this review).
The current development of COXIBs in the chemopre-
vention ﬁeld depends on their cardiovascular safety proﬁle.
3.3. Other Drugs. Few additional agents have been studied
with success in PAF. However, one study has recently been
published, but it was unable to demonstrate an eﬀect. In
theConcertedActionPolypPrevention(CAPP)study,young
individuals with APC mutations were randomised using a 2
× 2 factorial design comparing 30g of resistant starch and
600mgofaspirinversusplacebofor1to12years[41].Inthis
study, 206 patients were enrolled, with only 133 used in the
analysisofthedata.Thestudywasnegativeforallarmsforits6 The Scientiﬁc World Journal
main objective (number of adenomas in rectum and sigmoid
colon) and for its secondary endpoint (size of adenomas),
with no reported side eﬀects of interest.
4. LynchSyndrome andCRC
Lynch syndrome (LS), also called hereditary nonpolyposis
colorectal cancer (HNPCC), predisposes individuals at a
young age to the development of CRC and other tumours
[42].Thegermlinemutationsthatproducethissyndromeare
located in the MMR genes (MLH1, MSH2, MSH6, PMS2).
MLH1 mutations are present in 50% of cases, and MSH2
mutations are present in 40% of cases [43].
Microsatellites are susceptible to DNA replication errors
when the MMR system is not working correctly. However,
15% of sporadic CRCs can present microsatellites instability
(MSI) without a germline mutation in MMR genes; this
is related to the somatic hypermetilation of the MLH1
promoter.
CRCs in LS have speciﬁc characteristics, such as early age
at diagnosis, multiplicity, and family history [44].
Clinical management of CRC consists of surveillance
with colonoscopies; additionally, the rarer possibility of pro-
phylactic surgical evaluation exists. The periodic surveillance
programs have reducedthe CRC mortality in this population
approximately 60% [45].
Chemoprevention is currently under investigation in
CRCprevention.ThemolecularunderstandingofLSleadsto
hypotheses regarding the reduction of the incidence of CRC
in this group. The close relationship between MMR genes
and inﬂammatory pathways has led to the development of
clinical trials with diﬀerent inhibitors in LS.
4.1. Aspirin. In preclinical models, aspirin suppressed muta-
tion phenotypes and increased MMR protein expression
in MMR-deﬁcient cell lines [46, 47]. In sporadic CRC
populations, there is evidence that aspirin leads to a
reduction of adenomas. Speciﬁcally, in LS, the CAPP2 study
analysed the role of aspirin versus placebo (plus starch)
in MMR germline mutation carriers. Initially, the trial did
not demonstrate a beneﬁt for aspirin; however, 5 years
after randomisation, diﬀerences were observed between the
placebo and aspirin groups. Furthermore, 9 years after
randomisation, the aspirin group showed a 50% reduction
in CRC incidence, and this eﬀect was stronger in those who
received aspirin over 2 years [48].
These results have lead to the evaluation of other drugs,
such as celecoxib, that stimulate the TGF-beta signalling
pathway. Some studies have shown that speciﬁc COX-2
inhibitors may have a higher impact in reducing the number
of polyps in mice in contrast with placebo or sulindac [49].
4.2.Sulindac. Sulindac,awell-knownchemopreventivedrug
used in adenomatous familial polyposis (AFP), inhibited
tumour growth in APC mutant mice but increased tumour
appearance in MLH1 mutant mice. Furthermore, additional
studieshavefounddiﬀerencesinadenomacontrolinrelation
to the size and location of the adenomas.
5. Conclusion
After reviewing the available data from randomised clinical
trials and meta-analysis, it is diﬃcult to draw conclusions
regarding the eﬀectiveness of NSAIDs and COXIBs in CRC
chemoprevention. Both ASA and COXIBs reduce adenoma
incidence and, perhaps, they could have an eﬀect on CRC
development; however there is lack of comparative trials
between these agents. Thus, their impact in CRC mortality
is unknown. Dose and duration of treatment remind to
be determined and their safety proﬁle may limit their use,
mainly in healthy individuals. While promising, more long-
term trials are needed in order to set the role of these
agents in this ﬁeld while other areas such as Lynch syndrome
need further investigations. Currently, there is only one
drug, celecoxib, approved by the regulatory agencies for
chemoprevention, in patients with PAF. Inspite of the fact
that there is no chemopreventive strategy able to replace
surgery and endoscopic surveillance in these patients, it can
be seen as an option in selected cases to delay the time of
surgery or as secondary prevention if there is persistence of
adenomas after prophylactic surgery.
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